Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-003 Injection in Patients With Advanced Malignancies
Latest Information Update: 23 May 2024
At a glance
- Drugs LBL-003 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Leads Biolabs
- 17 May 2024 Status changed from recruiting to completed.
- 08 Dec 2023 Planned End Date changed from 22 Dec 2023 to 22 Jul 2024.
- 08 Dec 2023 Planned primary completion date changed from 22 Oct 2023 to 22 Mar 2024.